Scarletred

SCARLETRED is the global leader in AI assisted objective skin imaging and disease analysis Dr. Harald Schnidar MBA.

SCARLETRED Holding GmbH develops innovative products for augmented digital skin analysis, personalised medicine and therapy. The company is headquartered in Vienna and was founded in 2012 by the Molecular Biologist Mag.

28/08/2026

🔬 SCARLETRED research to be presented at ESDR 2026!

We are proud that our latest research will be featured at the 55th Annual ESDR Meeting, Europe's leading conference for skin research and dermatological science, taking place from September 9-12 in Heidelberg, Germany.

Two posters will showcase AI-driven imaging, analysis and disease severity scoring capabilities - covering objective skin typing and Epidermolysis Bullosa. All built on our CE-certified SaMD Scarletred®Vision, powered by ARORA®AI.

📅 Save the date:
📌 55th Annual ESDR Meeting
📌 September 9-12, 2026
📌 Heidelberg, Germany

27/08/2026

12 years, one core mission, making skin measurable. 🚀

Today, SCARLETRED celebrates its 12th anniversary.

What started in 2014 as a clinical imaging platform has evolved into Digital Skin Intelligence - combining standardized smartphone imaging, quantitative skin biomarkers, and medical AI to turn skin data into meaningful clinical insights.

12 years of science, clinical evidence, technology, and collaboration across 30+ countries.

From clinical research to routine care and the patient’s home, remote skin assessment is the future of digital dermatology - making objective skin data more accessible, scalable, and actionable.

Thanks to our partners, clinicians, researchers, patients, and everyone who has been part of the journey 🌟

Going beyond imaging - turning skin data into intelligence for better clinical decisions🌍

25/08/2026

What if assessing a chronic skin disease was as simple as taking a photo? 📲

100 to 125 million people worldwide live with psoriasis – an autoimmune disease often linked to cardiovascular disease, diabetes and in 30 percent of the cases to psoriatic arthritis.

Psoriasis goes way beyond the visible plaques. The disease touches both physical and mental health – directly impacting daily quality of life.

For many, tracking psoriasis severity (PASI) still means frequent in-clinic visits.

Scarletred®Vision is proof that there is another way: Tracking from home, scoring from anywhere.

🔎 Swipe through our gallery to see how we reduce in-clinic visits with a smartphone.

24/08/2026

🔒 SCARLETRED is now ISO/IEC 27001:2022 certified.

SCARLETRED is proud to announce its ISO/IEC 27001:2022 certification - the international benchmark for Information Security Management Systems.

Following an independent audit, this certification confirms that our approach to protecting patient, customer and clinical data meets the highest international standard.

🔊 “Achieving ISO/IEC 27001:2022 is an important milestone, but more importantly, it is the independent confirmation that the systems and discipline we have built around data protection meet the highest international standard”, says Dr. Harald Schnidar, CEO & Founder of SCARLETRED.

The certification adds to 's existing regulatory foundation as a CE-certified Software as a Medical Device (SaMD), as we continue scaling Scarletred®Vision, powered by ARORA®AI, with partners worldwide.

Read more here: https://www.scarletred.com/news/scarletred-is-now-iso-iec-27001-2022-certified

31/07/2026

🔎 Skin pigmentation disorders are widespread, yet widely misunderstood and often monitored with inconsistent methods.

Traditional skin assessment tools have served dermatology for decades, but they share one limitation: subjectivity.

SCARLETRED is changing that:

📲 Scarletred®Vision delivers objective, standardized pigmentation monitoring via smartphone.

👉 Swipe through to learn more about hyperpigmentation:
Its root causes, its risk groups, and how it can be monitored with precision.

What is your experience grading pigmentation in practice - where do subjective methods fall short for you?

28/07/2026

Summer is in full swing. Make sure your UV safety is too. ⛱️

☀️ Ultraviolet (UV) radiation from the sun accounts for 80% to 90% of all diagnosed skin cancer cases. Skin cancer incidence is rising globally – with over 1.5 million new cases diagnosed each year.

But not all skin carries the same risk:

🔬 Your Fitzpatrick Skin Type (I-VI) helps determine how your skin reacts to sun exposure. It is shaped by your eye, hair and skin color, and defines how much protection you truly need.

🔎 However, guessing your own phototype is not fully reliable.

📲 This is where Scarletred®Vision delivers precision: Combining the Fitzpatrick scale with a clinically validated color space and the Individual Typology Angle (ITA°) to deliver objective, AI-powered skin type analysis from one single photograph.

👉 We have summarized what you can do for your skin this summer to stay protected – swipe through our gallery to learn more.

®AI

Sources: WHO, American Cancer Society, European Commission, AAD.

23/07/2026

🔎 Is AI about to replace the dermatologist?

Scarletred®Vision is proof that smartphone images can change how skin conditions are monitored and analyzed - in clinical trials, routine care, and patients' homes worldwide.

This is why we introduce our new Podcast format - the podcast for digital dermatology and agentic AI.

In our first episode, SCARLETRED CEO & Founder Dr. Harald Schnidar sits down with Prof. Dr. Apostolos Pappas - pioneer in human cell research, author, and international keynote speaker at the world's leading dermatology conferences.

Together, they explore:
💡 How mobile skin imaging and AI analysis are transforming drug development and clinical trials
💡 How Scarletred®Vision quantifies mobile images for clinically validated skin analysis
💡 How ARORA®AI is meeting the needs of biopharma, cosmetics & aesthetics
💡 The human side of innovation - and why AI is a collaborator, not a competitor

🎙️ Watch Episode #1 now on YouTube: https://youtu.be/mTPX5t5zyzY

What do you think about AI in dermatology? More to come - stay tuned!

08/07/2026

🔬Today is World Skin Health Day!

This year's theme - better knowledge, better skin health - is one we live by.

Skin health should not depend on where you live or who you have access to. It should depend on getting clear, accurate answers - wherever you are.

🔎That is why we built Scarletred®Vision:

Smartphone-based skin imaging and monitoring that brings objective, data-driven insight to patients and clinicians worldwide.

📌 Recognized for more than 3.000 skin conditions – so more people get accurate answers, sooner.
📌 Available globally, on iOS and Android – so distance is not the barrier to good care.
📌 Built on strict data protection and clinical standards – so trust is not a trade-off.

Better knowledge. Better care. Worldwide. 🌍 With Scarletred®Vision. 📲

30/06/2026

Over 780 million people live with acne worldwide. Yet it remains one of the most misunderstood skin conditions globally.

is one of the most prevalent chronic skin conditions across all life stages – and one of the most underestimated.

Beyond breakouts, acne carries a significant psychological burden: anxiety, depression, and social withdrawal are widespread and often overlooked.

Effective care starts with accurate assessment:

🔎 Scarletred®Vision enables mobile, objective, AI-powered documentation, lesion quantification, and longitudinal monitoring of acne.

🔗 Read more in our article: https://www.scarletred.com/articles/transforming-acne-treatment-and-research-with-scarletred-r-vision

👉 Swipe through our gallery to find out more!

®AI

29/06/2026

SCARLETRED is published in JAAD - the Journal of the American Academy of Dermatology 🔬

📄 "AI-Powered Imaging for Objective Psoriasis Severity Assessment at Home: Feasibility and Reliability in a Randomized Clinical Trial"

🔗 Read the publication here: https://doi.org/10.1016/j.jaad.2026.06.047

The brief report demonstrates that AI-powered smartphone imaging can reliably assess psoriasis severity in the home setting - reducing the need for frequent clinic visits while delivering objective, consistent disease monitoring at scale.

We are proud to have Monika Molnarova and Dr. Harald Schnidar, CEO of SCARLETRED, among the contributing authors of this publication.

🔊 “This peer-reviewed publication in JAAD marks a major milestone for our team and validates the rigorous clinical science behind our technology. The study confirms that standardized mobile imaging, together with SCARLETRED’s ®AI, can generate reliable primary clinical endpoint data in psoriasis, both in the clinic and in a decentralized home setting”, says Dr. Harald Schnidar, CEO and Founder of SCARLETRED.

🔊 "This study shows that high-quality, objective skin assessment no longer has to happen inside a clinic. This proof has real implications for how we design care for patients with chronic skin conditions”, adds Monika Molnarova, Biomedical Engineer and Senior Data Scientist at SCARLETRED.

Thank you to all co-authors and contributors:

Mariona Oliver, Menthe Bergmans, Jannik Rousel, Tessa Niemeyer - van der Kolk, MD PhD, Marieke Seyger, Leonard Wee, Deepak Balak, Martijn van Doorn, Robert Rissmann, and Next Generation ImmunoDermatology Consortium (NGID).

Adresse

MQM3. 4, Maria Jacobi Gasse 1, 8th Floor
Wien
1030

Telefon

+436644669807

Webseite

https://scarletred.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Scarletred erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.